Kurse werden geladen...
Prognose
Kaufen | 1 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”). The Reverse Stock Split is intended to increase the market price per share of the Company's Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the “NYSE American”) in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and into LNHC, Inc. and the related approximately $50 million in capital to be raised from a group of strategic investors led by Murchinson (together, the “Proposed Transactions”).» Mehr auf globenewswire.com
Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules
FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph.» Mehr auf globenewswire.com
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical's recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −1,82 Mio | 23,39% |
EBITDA | −1,70 Mio | 5,40% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 7,59 Mio€ |
Anzahl Aktien | 6,60 Mio |
52 Wochen-Hoch/Tief | 46,29€ - 1,05€ |
Dividenden | Nein |
Beta | 3,29 |
KGV (PE Ratio) | −1,12 |
KGWV (PEG Ratio) | −0,13 |
KBV (PB Ratio) | −1,97 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Chromocell Therapeutics Corporation, ein Biotech-Unternehmen in der klinischen Phase, konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung neuer Therapeutika zur Schmerzlinderung. Das Unternehmen beabsichtigt, selektiv auf den als NaV1.7 bekannten Natrium-Ionenkanal sowie auf andere Rezeptoren der NaV-Familie einzuwirken. Die Leitsubstanz CC8464 befindet sich in klinischen Phase-2a-Studien zur Behandlung von Erythromelalgie und anderen Formen neuropathischer Schmerzen. Chromocell Therapeutics Corporation wurde im Jahr 2002 gegründet und hat seinen Sitz in Freehold, New Jersey.
Name | CHROMOCELL THERAP. CORP. Aktie |
CEO | Francis Knuettel II, |
Sitz | Freehold, nj USA |
Website | |
Industrie | Gesundheitstechnologie |
Börsengang | |
Mitarbeiter | 4 |
Ticker Symbole
Börse | Symbol |
---|---|
AMEX | CHRO |
Assets entdecken
Shareholder von CHROMOCELL THERAP. CORP. Aktie investieren auch in folgende Assets